Literature DB >> 20852487

Sorafenib in hepatocellular carcinoma.

Debra H Josephs1, Paul J Ross.   

Abstract

Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20852487     DOI： 10.12968/hmed.2010.71.8.77669

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN： 1750-8460            Impact factor:   0.825


  5 in total

Review 1.  Back to the future: oral targeted therapy for RA and other autoimmune diseases.

Authors:  John J O'Shea; Arian Laurence; Iain B McInnes
Journal:  Nat Rev Rheumatol       Date:  2013-02-19       Impact factor: 20.543

2.  Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Authors:  Vladimir Beljanski; Clayton S Lewis; Charles D Smith
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

3.  Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.

Authors:  D Vara; M Salazar; N Olea-Herrero; M Guzmán; G Velasco; I Díaz-Laviada
Journal:  Cell Death Differ       Date:  2011-04-08       Impact factor: 15.828

4.  Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.

Authors:  Yun-Qing Qiu; Jue Zhou; Xin-Shan Kang; Lie-Ming Ding; Wei Yu; Fen-Lai Tan; Dan-Feng Deng
Journal:  Sci Rep       Date:  2014-03-17       Impact factor: 4.379

Review 5.  Implication of the Hedgehog pathway in hepatocellular carcinoma.

Authors:  Carminia Maria Della Corte; Giuseppe Viscardi; Federica Papaccio; Giovanna Esposito; Giulia Martini; Davide Ciardiello; Erika Martinelli; Fortunato Ciardiello; Floriana Morgillo
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.